Investor Relations

Investor Presentation

View our latest Investor Presentation to find the most recent investor-related information.

Latest Financial Results

Q2 2024

Quarter Ended Jun 30, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

The company is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The company’s most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and is currently being evaluated in a Phase 1/2 open-label, dose-escalation trial, with encouraging early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy. Phentolamine Ophthalmic Solution 0.75% is currently being evaluated in Phase 3 trials for presbyopia and dim (mesopic) light vision disturbances.

Stock Snapshots

IR Contacts

Headquarters

Opus Genetics, Inc.
37000 Grand River Ave., Suite 120
Farmington Hills, MI 48335
T: 248-957-9024
ir@ocuphire.com

Investor Relations

LifeSci Advisors
250 West 55th Street, Suite 3401
New York, NY 10019
T: 646-889-1200
cdavis@lifesciadvisors.com

Transfer Agent

Equiniti Trust Company, LLC (“EQ”)
48 Wall Street, Floor 23
New York, NY 10005
T: 800-468-9716
https://www.equiniti.com